Atai reports its Q2 2022 results, announces a new $175 million loan facility and streamlines its operations.

Mind Medicine announces a reverse share split of its common shares at a 1-15 ratio. Exchange symbols will remain the same but new CUSIP numbers will be assigned by the appropriate regulators.

Compass Pathways reports its Q2 2022 results. Preparing for its Phase 3 clinical trial for TRD. Net loss of $21.0 million. Cash (and equivalents) of $207.2 million.

Compass Pathways announces the launch of a Phase II clinical trial using psilocybin-based COMP360 as a treatment for anorexia nervosa.

Red Light Holland acquires two of the Netherlands premier shops for psychedelic truffles and wellness products.

Awakn Life Sciences announces UK government grant funding to cover 2/3rds of the costs of its Phase III clinical trial for alcohol use disorder (AUD).

Pasithea Therapeutics announces being awarded a research grant of AUD $1 million (US$694,000) for its psychedelics-based research for ALS disease.

Compass Pathways announces that Kabir Nath will replace George Goldsmith as CEO effective August 1, 2022.

Better Life Pharma announces additional funding to study BETR-001 as a treatment for depression, via the Mitacs Accelerate program.

Red Light Holland announces a partnership with platinum-selling rapper, Wiz Khalifa, to launch Red Light Holland’s MISTERCAP brand of psilocybin-based products.